The U.S. Food and Drug Administration approved Boehringer Ingelheim’s nerandomilast, to be marketed as Jascayd, for idiopathic pulmonary fibrosis (IPF). The decision, announced Oct. 7, 2025, follows phase 3 data showing a slower decline in lung function versus placebo and earned the drug Breakthrough Therapy designation earlier in development. Boehringer, which already markets the IPF therapy Ofev, pitched Jascayd as an oral PDE4B inhibitor with a distinct safety and tolerability profile. Leerink Partners analysts described the approval as a modest but important advance given the long gap in new IPF therapies and said solid uptake is likely despite a relatively modest effect size. Boehringer has not disclosed pricing; the company framed Jascayd as an addition—rather than a replacement—to its existing ILD portfolio and noted plans to discuss the data and next steps with regulators and payers. The approval reshuffles options in a small but clinically urgent market with several competitors advancing.